Ligand Pharmaceuticals (LGND) Revenue & Revenue Breakdown
Ligand Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$131.31M
Latest Revenue (Q)
$41.53M
Main Segment (Y)
Material Sales, Captisol
Ligand Pharmaceuticals Revenue by Period
Ligand Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $131.31M | -33.09% |
| 2022-12-31 | $196.25M | -29.19% |
| 2021-12-31 | $277.13M | 48.66% |
| 2020-12-31 | $186.42M | 54.98% |
| 2019-12-31 | $120.28M | -52.17% |
| 2018-12-31 | $251.45M | 78.21% |
| 2017-12-31 | $141.10M | 29.48% |
| 2016-12-31 | $108.97M | 51.53% |
| 2015-12-31 | $71.91M | 11.43% |
| 2014-12-31 | $64.54M | 31.78% |
| 2013-12-31 | $48.97M | 56.03% |
| 2012-12-31 | $31.39M | 4.50% |
| 2011-12-31 | $30.04M | 27.61% |
| 2010-12-31 | $23.54M | -39.55% |
| 2009-12-31 | $38.94M | 42.56% |
| 2008-12-31 | $27.32M | 111.84% |
| 2007-12-31 | $12.89M | -90.85% |
| 2006-12-31 | $140.96M | -20.18% |
| 2005-12-31 | $176.61M | 8.01% |
| 2004-12-31 | $163.51M | 15.85% |
| 2003-12-31 | $141.14M | 46.05% |
| 2002-12-31 | $96.64M | 26.59% |
| 2001-12-31 | $76.34M | 58.68% |
| 2000-12-31 | $48.11M | 17.63% |
| 1999-12-31 | $40.90M | 131.07% |
| 1998-12-31 | $17.70M | -65.76% |
| 1997-12-31 | $51.70M | 40.49% |
| 1996-12-31 | $36.80M | 50.20% |
| 1995-12-31 | $24.50M | 84.21% |
| 1994-12-31 | $13.30M | - |
Ligand Pharmaceuticals generated $131.31M in revenue during NA 2023, up -33.09% compared to the previous quarter, and up 52.22% compared to the same period a year ago.
Ligand Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $41.53M | 34.07% |
| 2024-03-31 | $30.98M | 10.24% |
| 2023-12-31 | $28.10M | -14.50% |
| 2023-09-30 | $32.87M | 24.66% |
| 2023-06-30 | $26.37M | -40.05% |
| 2023-03-31 | $43.98M | -12.71% |
| 2022-12-31 | $50.38M | -23.77% |
| 2022-09-30 | $66.09M | 15.10% |
| 2022-06-30 | $57.42M | 25.66% |
| 2022-03-31 | $45.69M | -36.95% |
| 2021-12-31 | $72.47M | 11.78% |
| 2021-09-30 | $64.83M | -23.43% |
| 2021-06-30 | $84.67M | 53.54% |
| 2021-03-31 | $55.15M | -21.20% |
| 2020-12-31 | $69.99M | 67.25% |
| 2020-09-30 | $41.85M | 1.03% |
| 2020-06-30 | $41.42M | 24.91% |
| 2020-03-31 | $33.16M | 22.80% |
| 2019-12-31 | $27.00M | 8.85% |
| 2019-09-30 | $24.81M | -0.72% |
| 2019-06-30 | $24.99M | -42.54% |
| 2019-03-31 | $43.48M | -27.03% |
| 2018-12-31 | $59.59M | 30.50% |
| 2018-09-30 | $45.66M | -49.29% |
| 2018-06-30 | $90.04M | 60.34% |
| 2018-03-31 | $56.16M | 11.28% |
| 2017-12-31 | $50.46M | 51.20% |
| 2017-09-30 | $33.38M | 19.22% |
| 2017-06-30 | $28.00M | -4.35% |
| 2017-03-31 | $29.27M | -23.35% |
| 2016-12-31 | $38.19M | 76.63% |
| 2016-09-30 | $21.62M | 10.75% |
| 2016-06-30 | $19.52M | -34.16% |
| 2016-03-31 | $29.65M | 39.90% |
| 2015-12-31 | $21.19M | 19.72% |
| 2015-09-30 | $17.70M | -3.89% |
| 2015-06-30 | $18.42M | 26.13% |
| 2015-03-31 | $14.60M | -36.51% |
| 2014-12-31 | $23.00M | 53.60% |
| 2014-09-30 | $14.97M | 41.15% |
| 2014-06-30 | $10.61M | -33.53% |
| 2014-03-31 | $15.96M | 8.29% |
| 2013-12-31 | $14.74M | 13.32% |
| 2013-09-30 | $13.01M | 35.75% |
| 2013-06-30 | $9.58M | -17.78% |
| 2013-03-31 | $11.65M | -14.55% |
| 2012-12-31 | $13.63M | 113.88% |
| 2012-09-30 | $6.38M | 11.02% |
| 2012-06-30 | $5.74M | 1.88% |
| 2012-03-31 | $5.64M | -56.43% |
| 2011-12-31 | $12.94M | 125.33% |
| 2011-09-30 | $5.74M | -23.07% |
| 2011-06-30 | $7.46M | 91.56% |
| 2011-03-31 | $3.90M | -1.12% |
| 2010-12-31 | $3.94M | -49.50% |
| 2010-09-30 | $7.80M | 33.64% |
| 2010-06-30 | $5.84M | -2.01% |
| 2010-03-31 | $5.96M | -57.37% |
| 2009-12-31 | $13.98M | 76.90% |
| 2009-09-30 | $7.90M | 4.04% |
| 2009-06-30 | $7.59M | -19.81% |
| 2009-03-31 | $9.47M | -23.56% |
| 2008-12-31 | $12.39M | 136.07% |
| 2008-09-30 | $5.25M | 9.24% |
| 2008-06-30 | $4.80M | -1.44% |
| 2008-03-31 | $4.87M | -15.53% |
| 2007-12-31 | $5.77M | - |
Ligand Pharmaceuticals generated $41.53M in revenue during Q2 2024, up 34.07% compared to the previous quarter, and up 94.43% compared to the same period a year ago.
Ligand Pharmaceuticals Revenue Breakdown
Ligand Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 22 | Dec 21 | Dec 20 | Dec 19 | Dec 18 |
|---|---|---|---|---|---|
| Material Sales, Captisol | $104.50M | $164.25M | $109.96M | $31.49M | $29.12M |
| Service | $1.12M | $23.71M | $21.80M | - | - |
| Royalty, Other | $7.63M | $11.38M | $2.57M | - | - |
| Royalty, Kyprolis | $30.12M | $27.47M | $25.05M | - | - |
| Royalty, Evomela | $10.20M | $10.08M | $5.17M | - | - |
| Royalty | $72.53M | $48.93M | $46.98M | - | - |
| Milestone | $9.15M | $28.75M | $11.52M | $23.45M | $6.58M |
| Material Sales, Captisol, Core | $16.43M | - | - | - | - |
| Material Sales, Captisol, COVID | $88.07M | - | - | - | - |
| License Fees | $2.85M | $5.08M | $4.38M | $6.20M | $78.19M |
| License Fees, Milestones, and Other Product, Other | $6.11M | $6.41M | $4.97M | $12.17M | $9.00M |
| Contract Revenue | $19.22M | $63.96M | $42.66M | - | - |
| License Fees, Milestones, and Product, Other | - | - | - | $41.82M | $93.77M |
| Royalty, Promacta | - | - | - | $14.19M | - |
Ligand Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 22: Material Sales, Captisol (28.40%), Material Sales, Captisol, COVID (23.94%), Royalty (19.71%), Royalty, Kyprolis (8.19%), Contract Revenue (5.22%), Material Sales, Captisol, Core (4.47%), Royalty, Evomela (2.77%), Milestone (2.49%), Royalty, Other (2.07%), License Fees, Milestones, and Other Product, Other (1.66%), License Fees (0.77%), and Service (0.30%).
Quarterly Revenue by Product
| Product/Service | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Sep 21 | Jun 21 | Mar 21 | Sep 20 | Jun 20 | Mar 20 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Royalty | $20.43M | $17.15M | $21.04M | $19.84M | $17.96M | $13.70M | $15.65M | $8.62M | $7.11M | $9.01M | $7.18M | $6.57M | $20.80M | - | - | - | - | - |
| Rylaze | $3.03M | $2.61M | $2.10M | $2.32M | $1.65M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Royalty, Other | $3.33M | $2.27M | $3.78M | $1.42M | $619.00K | $1.81M | $4.16M | $983.00K | $492.00K | $280.00K | $501.00K | $584.00K | - | - | - | - | - | - |
| Teriparatide Injection | $3.61M | $3.50M | $4.07M | $5.50M | $2.91M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Milestone | - | $15.30M | $-4.87M | $3.66M | $1.27M | $9.09M | $7.42M | $3.60M | $8.42M | $960.00K | $1.92M | $2.83M | - | - | - | - | - | - |
| Material Sales, Captisol, Core | $5.22M | $10.62M | $3.30M | $3.58M | $3.33M | $6.23M | - | - | - | - | - | - | - | - | - | - | - | - |
| Material Sales, Captisol, COVID | - | - | $23.58M | $32.37M | $26.22M | $5.90M | - | - | - | - | - | - | - | - | - | - | - | - |
| Material Sales, Captisol | $5.22M | $10.62M | $26.88M | $35.95M | $29.55M | $12.12M | $35.09M | $62.51M | $31.27M | $23.39M | $7.61M | $4.39M | - | - | - | - | - | - |
| License Fees, Milestones, and Product, Other, Product, Other | $208.00K | $789.00K | $1.21M | $1.58M | $2.56M | $1.65M | $1.54M | $1.84M | $995.00K | $1.14M | $1.17M | - | - | - | - | - | - | - |
| License Fees | $508.00K | $114.00K | $-2.31M | $460.00K | $1.61M | $3.09M | $200.00K | $1.05M | $1.04M | $158.00K | $47.98M | $26.95M | - | - | - | - | - | - |
| Kyprolis | $8.10M | $6.23M | $9.12M | $7.13M | $4.62M | $8.82M | $5.44M | $4.29M | $6.92M | $5.48M | $4.41M | - | - | - | - | - | - | - |
| Evomela | $2.36M | $2.55M | $3.12M | $2.39M | $2.70M | $2.67M | $2.19M | $2.33M | $1.80M | $1.20M | $1.58M | - | - | - | - | - | - | - |
| Contract Revenue | $716.00K | $16.20M | $-20.87M | $10.30M | $9.91M | $19.88M | $14.09M | $13.55M | $16.77M | $9.45M | $5.19M | $2.13M | - | - | - | - | - | - |
| Contract Revenue, Service | - | - | - | $4.97M | $5.45M | $5.15M | $4.83M | $7.36M | $5.46M | $7.34M | - | - | - | - | - | - | - | - |
| Promacta | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $14.19M | - | - | - |
| Service | - | - | - | - | - | - | - | - | - | - | $4.58M | $3.36M | - | - | - | - | - | - |
| LicenseFeesMember | - | - | - | - | - | - | - | - | - | - | $660.00K | $975.00K | - | - | - | - | - | - |
| LicenseFeesMilestonesandProductOtherProductOtherMember | - | - | - | - | - | - | - | - | - | - | $1.06M | $821.00K | - | - | - | - | - | - |
| MaterialSalesCaptisolMember | - | - | - | - | - | - | - | - | - | - | $24.47M | $21.11M | $7.03M | - | - | - | - | - |
| MilestoneMember | - | - | - | - | - | - | - | - | - | - | $3.47M | $334.00K | - | - | - | - | - | - |
| LicenseFeesMilestonesandProductOtherMember | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $2.51M | - | - |
| License Fees, Milestones, and Product, Other | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $51.03M | $30.95M |
| Royalty, Evomela | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $1.60M |
| Royalty, Kyprolis | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.30M |
| Royalty, Product, Other | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $400.00K |
| Royalty, Promacta | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $15.60M |
Ligand Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 23: Royalty (38.74%), Kyprolis (15.36%), Material Sales, Captisol, Core (9.90%), Material Sales, Captisol (9.90%), Teriparatide Injection (6.85%), Royalty, Other (6.32%), Rylaze (5.74%), Evomela (4.47%), Contract Revenue (1.36%), License Fees (0.96%), and License Fees, Milestones, and Product, Other, Product, Other (0.39%).
Ligand Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BGNE | BeiGene | $2.46B | $929.17M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| LGND | Ligand Pharmaceuticals | $131.31M | $41.53M |
| RCUS | Arcus Biosciences | $117.00M | $39.00M |
| RLAY | Relay Therapeutics | $25.55M | - |
| CYTK | Cytokinetics | $7.53M | $249.00K |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| VRDN | Viridian Therapeutics | $314.00K | $72.00K |
| LYEL | Lyell Immunopharma | $130.00K | $3.00K |
| DSGN | Design Therapeutics | - | - |
| CGEM | Cullinan Oncology | - | - |
| GPCR | Structure Therapeutics | - | - |
| ANNX | Annexon | - | - |
| PASG | Passage Bio | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| ETNB | 89bio | - | - |
| ORIC | ORIC Pharmaceuticals | - | - |
| AKRO | Akero Therapeutics | - | - |
LGND Revenue FAQ
What is Ligand Pharmaceuticals’s yearly revenue?
Ligand Pharmaceuticals's yearly revenue for 2023 was $131.31M, representing a decrease of -33.09% compared to 2022. The company's yearly revenue for 2022 was $196.24M, representing a decrease of -29.19% compared to 2021. LGND's yearly revenue for 2021 was $277.13M, representing an increase of 48.66% compared to 2020.
What is Ligand Pharmaceuticals’s quarterly revenue?
Ligand Pharmaceuticals's quarterly revenue for Q2 2024 was $41.53M, a 34.07% increase from the previous quarter (Q1 2024), and a 57.52% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $30.98M, a 10.24% increase from the previous quarter (Q4 2023), and a -29.56% decrease year-over-year (Q1 2023). LGND's quarterly revenue for Q4 2023 was $28.1M, a -14.50% decrease from the previous quarter (Q3 2023), and a -44.22% decrease year-over-year (Q4 2022).
What is Ligand Pharmaceuticals’s revenue growth rate?
Ligand Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -52.62%, and for the last 5 years (2019-2023) was 9.17%.
What are Ligand Pharmaceuticals’s revenue streams?
Ligand Pharmaceuticals's revenue streams in c 22 are Material Sales, Captisol, Service, Royalty, Other, Royalty, Kyprolis, Royalty, Evomela, Royalty, Milestone, Material Sales, Captisol, Core, Material Sales, Captisol, COVID, License Fees, License Fees, Milestones, and Other Product, Other, and Contract Revenue. Material Sales, Captisol generated $104.5M in revenue, accounting 28.40% of the company's total revenue, down -36.38% year-over-year. Service generated $1.12M in revenue, accounting 0.30% of the company's total revenue, down -95.29% year-over-year. Royalty, Other generated $7.63M in revenue, accounting 2.07% of the company's total revenue, down -32.90% year-over-year. Royalty, Kyprolis generated $30.12M in revenue, accounting 8.19% of the company's total revenue, up 9.62% year-over-year. Royalty, Evomela generated $10.2M in revenue, accounting 2.77% of the company's total revenue, up 1.17% year-over-year. Royalty generated $72.53M in revenue, accounting 19.71% of the company's total revenue, up 48.24% year-over-year. Milestone generated $9.15M in revenue, accounting 2.49% of the company's total revenue, down -68.17% year-over-year. Material Sales, Captisol, Core generated $16.43M in revenue, accounting 4.47% of the company's total revenue Material Sales, Captisol, COVID generated $88.07M in revenue, accounting 23.94% of the company's total revenue License Fees generated $2.85M in revenue, accounting 0.77% of the company's total revenue, down -43.96% year-over-year. License Fees, Milestones, and Other Product, Other generated $6.11M in revenue, accounting 1.66% of the company's total revenue, down -4.76% year-over-year. Contract Revenue generated $19.22M in revenue, accounting 5.22% of the company's total revenue, down -69.94% year-over-year.
What is Ligand Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 22, the largest source of revenue of Ligand Pharmaceuticals was Material Sales, Captisol. This segment made a revenue of $104.5M, representing 28.40% of the company's total revenue.